Hit enter to search or ESC to close

Category: Investor Announcement

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

– Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) – – Expanding bioMUSE Natural History Study – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced an expansion of the clinical development program for the Company’s lead ...

Presentation of New Biomarker Data at Scientific Congress

Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International ...

Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s

Composition of Matter Patent Covers More than 80 Novel Compounds Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Office  (USPTO) has issued a Notice of Allowance for Alterity’s patent application No. 17/239,375. The composition ...

Quarterly Cash Flow Report

Highlights: Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial Publication in Movement Disorders demonstrates that ATH434 reduces α-synuclein related neurodegeneration in MSA animal model Presents to MST Access Australian Micro & Small Caps Conference Cash balance at 30 June 2021 of A$28M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or ...

New Publication Demonstrates ATH434 is Neuroprotective

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, has published results from a study demonstrating that ATH434 reduces α‑synuclein related neurodegeneration in a widely accepted ...
Senior male researcher carrying out scientific research

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).  The patent secures a broad monopoly over a new class of iron chaperones, a technology capable of redistributing excess iron in the central nervous ...

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Highlights: Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity’s plan to target early stage MSA patients. Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA. Agreement that ATH434 has potential as ...

Alterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases, today announced that Dr David Stamler, Chief Executive Officer will present a company overview at the MST Access Australian Micro & Small Caps Conference on Thursday 17 June 2021 at ...

Quarterly Cash Flow Report

Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appointed Chief Executive Officer Cash balance as at 31 March 2021 of A$32.8M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) releases its Appendix 4C Quarterly Cash Flow ...